Motley Fool Premium
  1. Stocks
    2. /
  2. AstraZeneca PLC (LSE: AZN)
    3. /

LSE:AZN (AstraZeneca PLC)

About AZN

AstraZeneca is a biopharmaceutical business that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three main therapy areas - Respiratory, Inflammation and Autoimmunity (RIA), Cardiovascular and Metabolic Disease (CVMD) and Oncology – as well as in Infection and Neuroscience.
Financial Market Data copyright © 2026 QuoteMedia. Data delayed 15 minutes unless otherwise indicated (view delay times for all exchanges). RT=Real-Time, EOD=End of Day, PD=Previous Day. Market Data powered by QuoteMedia. Terms of Use.

AstraZeneca PLC (LSE: AZN) Latest News

Investing Articles

How Strong Are AstraZeneca plc’s Dividends?

| Alan Oscroft

AstraZeneca plc (LON:AZN) can afford to keep handing out the cash for a couple more years or so.

Read more »

Investing Articles

AstraZeneca plc And Shire PLC Bolster Takeover Defences

| Rupert Hargreaves

Shire PLC (LON: SHP) and AstraZeneca plc (LON: AZN) are working to repel hostile buyers.

Read more »

Investing Articles

One Reason Why I Wouldn’t Buy AstraZeneca plc Today

| Royston Wild

Royston Wild explains why AstraZeneca plc (LON: AZN) is a poor growth selection.

Read more »

Investing Articles

Neil Woodford’s First Buys For His New Fund

| G A Chester

Disclosures by RM2 International SA (LON:RM2), ReNeuron Group Plc (LON:RENE), e-Therapeutics plc (LON:ETX); speculation on AstraZeneca plc (LON:AZN) and BAE…

Read more »

Investing Articles

Why Shire PLC’s Takeover Response Is Highly Unusual

| Peter Stephens

After Abbvie’s £27bn takeover offer was rejected, Shire PLC (LON: SHP) has responded in a rather unusual way...

Read more »

Company Comment

Look No Further Than AstraZeneca plc For Growth And Income

| Mark Stones

AstraZeneca plc's (LON: AZN) impressive drugs pipeline and ambitious revenue targets make it my preferred pharma stock.

Read more »

Investing Articles

Why Is AstraZenenca plc So Expensive?

| Alan Oscroft

Why AstraZenenca plc (LON: AZN) shares are looking pricey.

Read more »

Investing Articles

AstraZeneca plc’s Not So Secret Weapon

| Rupert Hargreaves

AstraZeneca plc's (LON: AZN) CEO is committed to the company.

Read more »

Investing Articles

This Thing Could Put A Rocket Under AstraZeneca plc’s Shares

| G A Chester

AstraZeneca plc (LON:AZN) has 35% potential upside.

Read more »

Investing Articles

A New Bid For AstraZeneca plc In November?

| Alan Oscroft

Pfizer may be back for another tilt at AstraZenenca plc (LON: AZN).

Read more »

Investing Articles

Should I Invest In AstraZeneca Plc Now?

| Kevin Godbold

Can AstraZeneca plc (LON: AZN) still deliver a decent investment return?

Read more »

Company Comment

Is AstraZeneca plc A Buy On $45bn Revenue Targets?

| Mark Stones

Will AstraZeneca plc's (LON: AZN) drugs pipeline live up to expectations?

Read more »